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Abstract
Background: Contrast-induced acute kidney injury (CI-AKI) is one of the most common causes of iatrogenic kidney
injury and, therefore, its prevention is an important issue. However, whether the administration of 0.9% saline is the
optimal prophylaxis method remains uncertain due to its supra-physiologic chloride component. In particular, recent
studies suggest that chloride-restricted solutions showed superiority over 0.9% saline in several clinical settings.
Methods/design: The investigators designed a multicenter randomized controlled trial to compare the efficacy of a
balanced salt solution and 0.9% saline in CI-AKI prophylaxis. This study will recruit patients who are scheduled for
contrast-enhanced computed tomography (CT) scans with CI-AKI prophylaxis. In this study, participants will be
randomized into two study arms; the study group will receive a balanced salt solution, and the control group will
receive 0.9% saline. Fluids will be administered as designated in the protocol before and after the CT scan, and an
evaluation of baseline clinical status will be performed by obtaining blood and urine samples. During the follow-up
visits, the incidence of CI-AKI and long-term outcomes, including the start of renal replacement therapy or all-cause
mortality, will be assessed.
Discussion: To our knowledge, this study will be the first study assessing the preventive value of a balanced salt
solution over 0.9% saline for CI-AKI. If the trial shows that the balanced salt solution is as effective for CI-AKI prophylaxis
as 0.9% saline, the use of the balanced salt solution could be promoted due to the reduced possibility of consequent
metabolic acidosis compared to 0.9% saline.
Trials registration: ClinicalTrials.gov, ID: NCT02799368. Registered on 14 June 2016.
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Background
Because iodinated contrast media is widely used in
current medicine [1, 2], its well-known side effect,
contrast-induced acute kidney injury (CI-AKI), has be-
come one of the most common causes of iatrogenic kid-
ney injury [3, 4]. CI-AKI has been related to increased
mortality, longer hospital stays and renal failure in pa-
tients with chronic kidney disease (CKD) [3, 5–9].
Hence, preventing CI-AKI has been regarded as an import-
ant medical issue [7, 10, 11], and the use of 0.9% saline has
been an essential part of CI-AKI prophylaxis [10, 12]. How-
ever, 0.9% saline has a pH of approximately 5.5 and con-
tains a supra-physiologic chloride level. Therefore, the use
of saline could cause metabolic acidosis, which contributes
to renal vasoconstriction [13, 14]. From this clinical point
of view, a few trials have tested the efficacy of a sodium bi-
carbonate fluid solution for CI-AKI prophylaxis, but the re-
sults failed to show consistent superiority over 0.9% saline
[15]. From another aspect, a recent clinical trial compared
the use of 0.9% saline and no prophylaxis for patients with
reduced kidney function, and showed no certain benefits
with 0.9% saline prophylaxis. However, the effect of CI-AKI
prophylaxis may be necessary to be tested in higher-risk pa-
tients, such as patients with other risk factors or even lower
baseline estimated glomerular filtration rate (eGFR) [16].
Recently, several human studies reported that meta-
bolic acidosis and vasoconstriction are less pronounced
when using a balanced salt solution, which has a physio-
logic level of chloride and a neutral pH, compared to
using 0.9% saline [17, 18]. Additionally, there were
prospective studies suggesting that using chloride-
restrictive solutions, rather than using chloride-rich
solutions, for fluid resuscitation can reduce acute kidney
injury (AKI) in critically ill patients [19, 20]. In accord-
ance with these findings, a large-scale cohort study was
reported, demonstrating the preventive effect of a bal-
anced salt solution for AKI over 0.9% saline [21].
Additionally, one clinical trial is currently recruiting par-
ticipants to prove the benefit of chloride-restrictive
fluids in cardiac surgery [22]. However, to the investiga-
tors’ knowledge, there are no ongoing trials regarding
the effectiveness of a balanced salt solution for CI-AKI
prophylaxis.
This multicenter randomized controlled trial is de-
signed to verify the effectiveness of a balanced salt
solution for CI-AKI prophylaxis. After randomization,
the study group will receive the balanced salt solution,
and the control group will receive 0.9% saline. In this
trial, the investigators will address whether the balanced
salt solution could be a potential standard solution for
CI-AKI prophylaxis.
Methods/design
The study is a randomized, open-label, active-control,
two-parallel-group, multicenter, phase-III study. The
study protocol is summarized in Figs. 1 and 2, the
latter showing the study timeline which accords with
the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) Figure. The main goal
is to evaluate whether using a balanced salt solution
Fig. 1 Study flow diagram
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is non-inferior to the use of 0.9% saline for CI-AKI
prophylaxis. In current medicine, many clinics provide
CI-AKI prophylaxis for patients with decreased kidney
function, and this study will recruit these patients
who are scheduled for contrast-enhanced computed
tomography (CT) scans. After participants are en-
rolled in the study with informed consent, they will
be randomized into the two study arms; the study
group will receive a balanced salt solution, and the
control group will receive 0.9% saline. The fluids for
CI-AKI prophylaxis will be administered as designated
in the protocol in the daycare center before and after
the CT scan. The baseline clinical status will be eval-
uated by obtaining blood and urine samples. Next,
the participants will be scheduled for a follow-up visit,
and their incidence of CI-AKI and further prognosis will
be evaluated. The protocol has been designed according
to the SPIRIT guidelines (see Additional file 1.)
Study participants
The study will recruit participants from the following 12
tertiary hospitals in Korea: Seoul National University
Hospital, Kyungpook National University Hospital, National
Medical Center, National Health Insurance Service Ilsan
Hospital, Seoul National University Bundang Hospital,
Bundang CHA Medical Center, Seoul St. Mary’s Hospital,
Seoul National University Boramae Medical Center,
Severance Hospital, Ewha Womans University Mokdong
Fig. 2 Study timeline and endpoints
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Hospital, Catholic Kwandong University International St.
Mary’s Hospital, and Gachon University Gil Medical Center.
The planned duration for the study enrollment completion
is 2 years. Below, we describe the inclusion and exclusion
criteria for the study participants, and the age or eGFR cut-
off values are based on a current clinical guideline [11].
Participants’ inclusion criteria are as follows:
1. Adult patients (age 18 years or older) who undergo
iodinated contrast-enhanced CT scans
2. Patients with a baseline eGFR, which is measured
within 3 months, of less than 45 mL/min/1.73 m2 or
both having a baseline eGFR less than 60 mL/min/
1.73 m2 and either one of the following risk factors:
(a)diabetes mellitus, or
(b)age 60 years or older
3. Patients who are able to provide informed consent
and give adequate information for the endpoint
assessment
Participants’ exclusion criteria are as follow:
1. Patients with a baseline eGFR of less than 15 mL/
min/1.73 m2 or who are on dialysis
2. Heart failure with a left ventricular ejection fraction
< 45% or severe symptoms (New York Heart
Association functional classification III or IV)
3. Co-existing acute pulmonary edema or
decompensated heart failure requiring the following
medications: dobutamine, dopamine, milrinone,
amrinone, or nesiritide
4. Patients with last measured serum potassium level >
5.5 mEq/L or serum sodium level > 145 mEq/L at
the screening period or within 3 months before the
CT scan
5. History of intravenous or intra-arterial administra-
tion of contrast agent within 1 week
6. Previous history of hypersensitivity reaction to the
iodinated contrast agent
7. History of multiple myeloma
8. Women who are currently pregnant/breastfeeding or
planning pregnancy
9. Patients with an expected survival duration of less
than 6 months
10.Patients who are already enrolled in another clinical
trial
Intervention protocols and fluids
The main intervention is the intravenous administration
of fluids for CI-AKI prophylaxis. The two types of fluid
used in our study are plasma solution A and 0.9% saline.
The study fluid, plasma solution A, will be manufactured
by CJ HealthCare Corporation, Seoul, South Korea and
in facilities following standards of Good Manufacturing
Practice. The provided product volume will be 1000 mL,
and plasma solution A will contain 5.26 g of sodium
chloride, 5.02 g of sodium gluconate, 3.68 g of sodium
acetate hydrate, 0.37 g of potassium chloride and 0.3 g
of magnesium chloride. In contrast, 0.9% saline will have
9.0 g of sodium chloride with a volume of 1000 mL. The
concentrations of each component of the two fluids are
summarized in Table 1. Plasma solution A, with
98 mEq/L of chloride, is the balanced salt solution used
in this study and will be administered to the study
group. Meanwhile, 0.9% saline, which is the standard
fluid for CI-AKI prophylaxis and contains 154 mEq/L of
chloride, will be used in the control group for CI-AKI
prophylaxis. Both fluids will be administered by the
designated rate, i.e., 3 mL/kg/h for 1 h before and
1.5 mL/kg/h for 4 h after the CT scans. Participants will
remain fasting during the fluid administration. All CT
scans will use iso- or low-osmolar contrast agents. N-
acetylcysteine will not be administered to the partici-
pants in this study as this medication lacks a definite
benefit for CI-AKI prophylaxis [23]. Other medication
use will not be restricted in the study.
Study endpoint
The primary endpoint of the study is the incidence of
CI-AKI. The event of CI-AKI will be defined as an in-
crease in the serum creatinine level ≥ 0.5 mg/dl or ≥ 25%
from baseline at 48–72 h after the CT scan [24]. For the
assessment of the primary endpoint, the patients will
visit the study hospital and a follow-up blood sample will
be drawn; along with other tests, serum creatinine will
be measured by the method that has been standardized
to isotope dilution mass spectrometry. Next, two sec-
ondary endpoints will be evaluated in the study; one is
the eGFR decrement at 48–72 h after the CT scan, and
the other is the start of dialysis, or mortality, which will
be assessed at 1 and 6 months, respectively. The eGFR
decrement will be assessed by the baseline and follow-up
eGFR values calculated by the serum creatinine as mea-
sured in the primary endpoint assessment. The eGFR will
Table 1 Components of the two fluids used in the study
0.9% saline Plasma solution A




Cl− (mEq/L) 154 98
Acetate (mEq/L) 27
Gluconate (mEq/L) 23
Osmolarity (mOsm/L) 308 295
pH 6.0 7.4
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be calculated using the Modification of Diet in Renal
Disease (MDRD) equation [25]. For documentation of
mortality and the beginning of dialysis, the study partici-
pants will be questioned via a direct visit or phone poll.
Sample size
The incidence of CI-AKI when using 0.9% saline for
prophylaxis was predicted according to the previous pro-
spective study (11.5%) [26]. In contrast, there was no
study regarding the incidence of CI-AKI after the use of
a balanced salt solution; therefore, the expected inci-
dence of CI-AKI in the study group was derived from
the prospective study, which compared the incidence of
AKI in an intensive care unit population according to
the resuscitation fluid use (8.4%) [20]. With a non-
inferiority limit of 1.5%, a total of 1660 study partici-
pants (830 in each group) would result in a power of at
least 80% with a one-sided type-1 error rate (α) of 2.5%,
allowing a 20% withdrawal rate in each group.
Blinding and randomization
The study is an open-label study; therefore, the type of
administered fluid will be disclosed both to the investi-
gators and the participants. The participants and their
information will be assigned a unique identifier number
at the time of initial enrollment and stored in a web-
based data collection system. The group allocation will
be performed after randomization in a 1:1 manner, at
least 3 h before contrast material administration. The
randomization scheme will be generated by using the
on-line randomization service developed by Sealed Enve-
lope Ltd. (www.sealedenvelope.com).
Statistical analysis
All primary and secondary endpoints and serious adverse
effects will be analyzed by the investigators at the partici-
pating hospitals. The final analysis will be completed at
6 months after the last participant’s trial. The primary
endpoint, i.e., the incidence of CI-AKI in the study and
control groups will be compared by a non-inferiority test
with 1.5% as the non-inferiority margin. The eGFR decre-
ment, one of the secondary endpoints in our study, will be
evaluated by chi-squared test. End-stage renal disease
(ESRD) progression and mortality will be assessed by
Kaplan-Meier survival curve with a log-rank test.
Data management
All participants’ information related to the study will be
recorded in the Case Reporting Format (CRF) and re-
corded in an electronic, password-protected database.
Study participants will only be recognized by their study
ID, and their personal identifier will not be recorded and
stored. All records will be accessed by the investigators
and authorized personnel only to secure confidentiality.
The investigators at each participating hospital will
monitor the completeness of the CRF. The database will
be locked and maintained for 10 years only for the pur-
pose of a secondary analysis or investigations by the at-
tending Institutional Review Boards (IRBs) and the
Korean Ministry of Food and Drug Safety (MFDS).
Adverse events
During the entire study period and after 30 days from
the end of the trial, adverse events (AE) will be reported
and recorded in the participants’ CRF. The severity of
AEs will be graded as mild, moderate and severe, and
their relationship between the study groups will also be
assessed by clinical judgement. If an AE requiring
hospitalization or causing a medically critical situation
occurs, the event will be recorded as a severe adverse
event (SAE). All SAEs will be reported to the investiga-
tor of the attending hospital and the IRB of reference
within 24 h after the information has been collected.
AEs that cannot deny a relationship to the study must
be followed until the AEs have been resolved. Whenever
AEs progress to the level of SAEs, the events must also
be reported according to the above protocol. At the time
of the study result submission, AEs and their relation-
ship to the study will be documented in a table and
submitted.
Discussion
Prophylaxis for CI-AKI is an important clinical issue be-
cause CI-AKI is common and worsens patient prognosis.
Although the use of 0.9% saline has been the standard
method for CI-AKI prophylaxis, its potentially harmful
effect was addressed in previous studies. There were sev-
eral efforts to find a more appropriate infusion fluid for
CI-AKI prophylaxis, but trials with sodium bicarbonate
fluid failed to demonstrate prophylactic efficacy. The
investigators considered the balanced salt solution to be
a potential fluid, which can replace 0.9% saline, due to the
balanced salt solution’s physiologic components and evi-
dence from recent study results. To our knowledge, the
study will be the first study assessing the preventive value
of a balanced salt solution over 0.9% saline for CI-AKI. If
the proposed trial demonstrates that the balanced salt so-
lution is effective for CI-AKI prophylaxis, the use of the
fluid could be promoted due to its reduced likelihood of
inducing metabolic acidosis. Therefore, the results of this
trial could be useful to improve the prophylaxis method
and, consequently, decrease the incidence of CI-AKI and
its adverse outcomes.
Trial status
The BASIC randomized controlled clinical study has re-
ceived governance approval and is registered at
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ClinicalTrials.gov (NCT02799368). The trial started re-
cruitment in November, 2016.
Additional file
Additional file 1: SPIRIT Checklist for the present study protocol.
(DOC 113 kb)
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